BMS Expands Manufacturing Agreement with Lonza

November 3, 2014
BioPharm International Editors

Bristol-Myers Squibb announced a multi-year expansion of its biologics manufacturing agreement with Lonza.

Bristol-Myers Squibb (BMS) announced on Oct. 30, 2014 that it would expand its existing biologics manufacturing agreement to include the production of commercial quantities of a second BMS biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire.

BMS and Lonza have collaborated since 2003 to produce commercial supplies of a biologics medicine. Lonza also produces clinical supplies of an investigational biologics medicine for BMS.

Source: Bristol-Myers Squibb